Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning (Publications)
available to treat diseases such as leishmaniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive
Ancistrotanzanine C and related 5,1'- and 7,3'-coupled naphthylisoquinoline alkaloids from <em>Ancistrocladus tanzaniensis</em> (Publications)
and chiroptical methods. The biological activities of the alkaloids against the pathogens causing malaria tropica, leishmaniasis, Chagas' disease, and African sleeping sickness were evaluated
Spatial epidemiology in zoonotic parasitic diseases: insights gained at the 1st International Symposium on Geospatial Health in Lijiang, China, 2007 (Publications)
and water-borne helminth infections, as well as arthropod-borne diseases such as leishmaniasis, malaria and lymphatic filariasis. The work made public at this occasion is briefly summarized here to highlight
Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design (Publications)
anticipated use of the intervention in target countries. Examples are provided from research on malaria vaccines that are also applicable to other new public health interventions
Discovery and structure-activity relationships of pyrrolone antimalarials (Publications)
2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways
<em>Plasmodium</em> sensitivity to artemisinins: magic bullets hit elusive targets (Publications)
the genetic basis of laboratory-induced or field-observed altered susceptibility is crucial for malaria control. In this review different models of artemisinins' molecular action are briefly presented
Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents (Publications)
thiolactomycin (TLM) have been synthesised and evaluated for their ability to inhibit the growth of the malaria parasite, Plasmodium falciparum. Thiolactomycin is an inhibitor of Type II fatty acid synthase which
Modified 5'-trityl nucleosides as inhibitors of <em>Plasmodium falciparum</em> dUTPase (Publications)
dine triphosphate nucleotidohydrolase (dUTPase) is a potential drug target for the treatment of malaria. We previously reported the discovery of 5'-tritylated analogues of deoxyuridine as selective inhibitors
Quantifying the impact of interventions against <em>Plasmodium vivax</em>: a model for country-specific use (Publications)
fictitious data, by simulating and comparing the impact of various intervention combinations on malaria risk and burden, this model could be a useful tool for strategic planning, implementation and resource
Ensuring transmission through dynamic host environments: host-pathogen interactions in <em>Plasmodium </em>sexual development (Publications)
A renewed global commitment to malaria elimination lends urgency to understanding the biology of Plasmodium transmission stages. Recent progress toward uncovering the mechanisms underlying Plasmodium